• Active, not recruiting

NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.

Updated: Apr 25

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."


total therapy myeloma

Locations

United States, Arkansas

University of Arkansas for Medical Sciences/Myeloma Institute


ClinicalTrials.gov Identifier: NCT00572169

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy - A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

First Posted : December 12, 2007


clinicaltrials.gov/ct2/show/NCT00572169


 

VDTPACE =

Velcade - Brtezomib

Thalidomide

Dexamethasone

Cisplatin

Adriamycin

Cyclophosphamide

Etoposide

 

Drug: Velcade

Drug: Thalidomide

Drug: Dexamethasone

Drug: Adriamycin

Drug: Cisplatin

Drug: Cyclophosphamide

Drug: Etoposide

 

Pawlyn C.

High-risk myeloma: a challenge to define and to determine the optimal treatment.

Lancet Haematol. 2021

https://pubmed.ncbi.nlm.nih.gov/33357481/

Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B.

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Blood. 2013 Jun

https://pubmed.ncbi.nlm.nih.gov/23603914/

Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F, Barlogie B.

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.

Blood. 2013 Mar

https://pubmed.ncbi.nlm.nih.gov/23305732/

Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Haematologica. 2012 Nov

https://pubmed.ncbi.nlm.nih.gov/22689675/

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Blood. 2012 Aug

https://pubmed.ncbi.nlm.nih.gov/22674807/



Posts Archive